NCT01642004 · OUTCOME
Overall Survival (OS) Rate in All Randomized Participants - Extended Collection
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) · Source last updated 2022-12-28
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent probability of OS
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From the date of randomization up to the specified timepoints, up to 84 months
What was measured
The overall survival rate is the probability that a participant will be alive at the specified timepoints following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.
Analysis population: All randomized participants
Groups in this outcome
Nivolumab
Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
Docetaxel
Docetaxel 75mg/m\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Nivolumab | 135 |
|---|
| Docetaxel | 137 |
|---|
Reported measurements
6 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 63.7 | Not reported | 55.0 | 71.2 | Not reported |
|---|
| Docetaxel | 50.4 | Not reported | 41.7 | 58.4 | Not reported |
|---|
12 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 42.2 | Not reported | 33.8 | 50.4 | Not reported |
|---|
| Docetaxel | 24.1 | Not reported | 17.3 | 31.5 | Not reported |
|---|
18 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 28.1 | Not reported | 20.8 | 35.9 | Not reported |
|---|
| Docetaxel | 12.4 | Not reported | 7.6 | 18.5 | Not reported |
|---|
24 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 23.0 | Not reported | 16.3 | 30.3 | Not reported |
|---|
| Docetaxel | 8.0 | Not reported | 4.3 | 13.3 | Not reported |
|---|
36 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 15.6 | Not reported | 10.0 | 22.2 | Not reported |
|---|
| Docetaxel | 5.8 | Not reported | 2.7 | 10.6 | Not reported |
|---|
48 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 13.1 | Not reported | 8.1 | 19.5 | Not reported |
|---|
| Docetaxel | 4.4 | Not reported | 1.8 | 8.8 | Not reported |
|---|
60 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 12.3 | Not reported | 7.4 | 18.5 | Not reported |
|---|
| Docetaxel | 3.6 | Not reported | 1.4 | 7.8 | Not reported |
|---|
72 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 11.4 | Not reported | 6.7 | 17.5 | Not reported |
|---|
| Docetaxel | 2.7 | Not reported | 0.8 | 6.7 | Not reported |
|---|
84 months
Values in Percent probability of OS · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Nivolumab | 9.6 | Not reported | 5.3 | 15.5 | Not reported |
|---|
| Docetaxel | 0.0 | Not reported | NA | NA | Lower and upper limit not calculated due to insufficient number of events. |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 55.0
- upper Limit
- 71.2
- value
- 63.7
- group Id
- OG001
- lower Limit
- 41.7
- upper Limit
- 58.4
- value
- 50.4
- title
- 6 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 33.8
- upper Limit
- 50.4
- value
- 42.2
- group Id
- OG001
- lower Limit
- 17.3
- upper Limit
- 31.5
- value
- 24.1
- title
- 12 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 20.8
- upper Limit
- 35.9
- value
- 28.1
- group Id
- OG001
- lower Limit
- 7.6
- upper Limit
- 18.5
- value
- 12.4
- title
- 18 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 16.3
- upper Limit
- 30.3
- value
- 23.0
- group Id
- OG001
- lower Limit
- 4.3
- upper Limit
- 13.3
- value
- 8.0
- title
- 24 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10.0
- upper Limit
- 22.2
- value
- 15.6
- group Id
- OG001
- lower Limit
- 2.7
- upper Limit
- 10.6
- value
- 5.8
- title
- 36 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 8.1
- upper Limit
- 19.5
- value
- 13.1
- group Id
- OG001
- lower Limit
- 1.8
- upper Limit
- 8.8
- value
- 4.4
- title
- 48 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.4
- upper Limit
- 18.5
- value
- 12.3
- group Id
- OG001
- lower Limit
- 1.4
- upper Limit
- 7.8
- value
- 3.6
- title
- 60 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.7
- upper Limit
- 17.5
- value
- 11.4
- group Id
- OG001
- lower Limit
- 0.8
- upper Limit
- 6.7
- value
- 2.7
- title
- 72 months
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5.3
- upper Limit
- 15.5
- value
- 9.6
- comment
- Lower and upper limit not calculated due to insufficient number of events.
- group Id
- OG001
- lower Limit
- NA
- upper Limit
- NA
- value
- 0.0
- title
- 84 months
- denoms
- counts
- group Id
- OG000
- value
- 135
- group Id
- OG001
- value
- 137
- units
- Participants
- description
- The overall survival rate is the probability that a participant will be alive at the specified timepoints following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
- id
- OG000
- title
- Nivolumab
- description
- Docetaxel 75mg/m\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.
- id
- OG001
- title
- Docetaxel
- param Type
- NUMBER
- population Description
- All randomized participants
- reporting Status
- POSTED
- time Frame
- From the date of randomization up to the specified timepoints, up to 84 months
- title
- Overall Survival (OS) Rate in All Randomized Participants - Extended Collection
- type
- POST_HOC
- unit Of Measure
- Percent probability of OS
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle